View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

LeMaitre to Participate at Upcoming Investor Conferences in March

LeMaitre to Participate at Upcoming Investor Conferences in March BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March. Leerink Partners Global Healthcare ConferenceTuesday, March 10, 2026W South Beach, MiamiManagement will present at 1:00 PM EDT Citizens Life Sciences ConferenceWednesday, March 11, 2026Eden Roc Miami Beach, MiamiManagement will present at 1:40 PM EDT Barclays Annual Global Healthcare ConferenceThursday, March 12, 2026Management wil...

 PRESS RELEASE

AMN Healthcare Survey Reveals Sharp Divide Between Leaders’ Organizati...

AMN Healthcare Survey Reveals Sharp Divide Between Leaders’ Organizational Confidence and Industry Outlook for 2026 Survey of 700+ executives shows AI leadership roles surging as succession planning and clinician engagement lag DALLAS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- While nearly three-quarters of healthcare executives believe their own organizations will be as strong or stronger in 2026, more than half expect the healthcare industry overall to face a worse year ahead, according to a new survey of healthcare executives. The findings highlight a widening confidence gap alongside a rapi...

 PRESS RELEASE

LeMaitre Q4 2025 Financial Results

LeMaitre Q4 2025 Financial Results BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024Gross margin 71.7% (+240 bps)Op. income $18.8mm (+47%)Op. margin 29%Diluted EPS $0.68 (+39%)Cash up $16.1mm sequentially to $359.1mm Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, ...

 PRESS RELEASE

Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025...

Apyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026 CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the ...

 PRESS RELEASE

UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Re...

UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(...

 PRESS RELEASE

AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results

AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(8%)Gross ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

 PRESS RELEASE

Apyx Medical Corporation to Participate in The Citizens Life Sciences ...

Apyx Medical Corporation to Participate in The Citizens Life Sciences Conference CLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. Charlie Goodwin, the Company’s President and Chief Executive Officer, and Matt Hill, the Company’s Chief Financial Officer, will participate in...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 14, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 2...

LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026 BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online . All registrants will receive dial-in information and a PIN allowing them to access the li...

Stryker Corp: 1 director

A director at Stryker Corp sold 500,000 shares at 363.439USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 6, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Stryker declares an $0.88 per share quarterly dividend

Stryker declares an $0.88 per share quarterly dividend Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the close of business on March 31, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services i...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Michael Piccolo
  • Michael Piccolo

Daily Recap: TASK, STAA, CCRN, HZO, AES, RNA, ARKO, FUBO, BARK, SITM, ...

TaskUs, Inc. (TASK - $11.11)AI Pivot Underway, We Think Up to the TASK; Mike Piccolo Initiating Coverage at OUTPERFORM with $15 Price Target. We are initiating coverage on TASK with an OUTPERFORM rating and a price target of $15 per share as we believe shares represent an attractive risk/reward opp

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch